Company’s ChIP assay will help validate prostate and liver cancer biomarkers.

Genpathway will help Upstream Biosciences validate its prostate and liver cancer biomarkers and drug response assay.
Upstream has identified specific genetic variations to use as diagnostic biomarkers for various forms of cancer.

Genpathway will use its ChIP assays to provide information for the next phase of the company’s program. The assays will help elucidate parameters involving specific gene transcription factors and pathways.

“This agreement with Genpathway,” notes Upstream CEO Joel Bellenson, “builds on the important analytic work we already have under way with NimbleGen and may allow us to acquire in-depth information that is not available with other analytic methods.”

Previous articlePTC Therapeutics Granted $15.4M for Duchenne Muscular Dystrophy Research
Next articleInvestigators Switch White Fat into Brown Fat in Mice